Advanced case of PKDL due to delayed treatment: A rare case report

Post-kala-azar dermal leishmaniasis (PKDL) is clinical outcome of visceral leishmaniasis (VL) and is thought to be the potential reservoir of parasite. Miltefosine (MF) is the only oral drug existing for treatment of post-kala-azar dermal leishmaniasis (PKDL). Increased miltefosine tolerance in clin...

Descripción completa

Detalles Bibliográficos
Autores principales: Topno, Roshan Kamal, Rabi Das, Vidya Nand, Kumar, Maneesh, Madhukar, Major, Pandey, Krishna, Verma, Neena, Agrawal, Kanhaiya, Lal, Chandra Shekhar, Siddiqui, Niyamat Ali, Bimal, Sanjiva, Das, Pradeep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Symposium
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7089400/
https://www.ncbi.nlm.nih.gov/pubmed/32203500
http://dx.doi.org/10.1371/journal.pntd.0008052
Descripción
Sumario:Post-kala-azar dermal leishmaniasis (PKDL) is clinical outcome of visceral leishmaniasis (VL) and is thought to be the potential reservoir of parasite. Miltefosine (MF) is the only oral drug existing for treatment of post-kala-azar dermal leishmaniasis (PKDL). Increased miltefosine tolerance in clinical isolates of Leishmania donovani has been reported and is one of the major concerns in the treatment of PKDL. Here, we report a highly ulcerated PKDL case that was successfully cured after miltefosine treatment.

Ejemplares similares